Clinical Trials Logo

Head and Neck Neoplasms clinical trials

View clinical trials related to Head and Neck Neoplasms.

Filter by:

NCT ID: NCT06237881 Recruiting - Melanoma Clinical Trials

A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors

Start date: January 31, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

To learn if KSQ-001EX is safe to give to participants with advanced forms of solid tumors.

NCT ID: NCT06224166 Recruiting - Clinical trials for Head and Neck Tumors

Analysis of HPV and Biomarkers Present in the Biological Fluids of Patients Suffering From Head and Neck Cancer as a Non-invasive Strategy for Detecting Recurrence

Start date: January 17, 2023
Phase:
Study type: Observational

Multicenter, non-interventional, retrospective/prospective biological study on patients affected by head and neck tumors, for which the collection and use of tissue samples, blood and saliva for the detection of HPV-DNA/RNA and miRNA.

NCT ID: NCT06216171 Recruiting - Clinical trials for Head and Neck Cancer

Adaptive Radiotherapy in Head and Neck Tumor Patients

ProHEART
Start date: January 25, 2024
Phase: N/A
Study type: Interventional

Most newly diagnosed oropharyngeal and hypopharyngeal cancers are treated with radiochemotherapy with curative intent. If the field-set UP margins are broad, the consequence may be that quality of life is impaired. The study group of Nutting et al. (2023) investigated this year whether dysphagia-optimized intensity-modulated radiotherapy can reduce the radiation dose to structures associated with dysphagia and aspiration and improve swallowing function compared to standard IMRT (Nutting C, Finneran L, Roe J, Petkar I, Rooney K, Hall E; DARS Triallist Group. Dysphagia-optimized intensity-modulated radiotherapy versus standard radiotherapy in patients with pharyngeal cancer - Authors' reply. Lancet Oncol. 2023 Oct;24(10):e398. doi: 10.1016/S1470-2045(23)00457-6. PMID: 37797636.) The study group concluded that the results suggest that dysphagia-optimized IMRT improves patient-reported swallowing function compared to standard IMRT. DO-IMRT should be considered the new standard of care for patients receiving radiotherapy for pharyngeal cancer, and ART could further improve outcomes.

NCT ID: NCT06215612 Not yet recruiting - Clinical trials for Head and Neck Neoplasms

ctDNA and MRI Parameters in Head and Neck Cancer

Start date: February 2024
Phase: N/A
Study type: Interventional

Patients undergoing primary radiochhemotherapy for locally advanced head and neck squamous cell carcinomas are included in this study. In addition to standard of care treatment patients will undergo addiational blood draws and MR imaging studies. Circulating cell free tumor DNA will be analysed in the blood samples. BIological data, imaging data and clinical data (such as patient and tumor characteristics, oncologic outcome, side effects) will be analysed in a biomathematical modelling approach.

NCT ID: NCT06214611 Recruiting - Clinical trials for Head and Neck Cancer

Prospective Validation of Adaptive Radiotherapy (ART) in Patients With Head and Neck Tumors

ART in HNT
Start date: November 15, 2023
Phase: N/A
Study type: Interventional

Adaptive radiotherapy (ART) includes image-guided radiotherapy (IGRT) and also offers further possibilities for plan adaptation. A particularly high benefit can be expected for patients in whom the clinical target volume (CTV) can show a significant change in shape from fraction to fraction due to anatomical deviations. The shape and position constancy of the CTV during the course of the series is examined in this trial. Dosimetric disadvantages of this type have not been reported so far. The aim of this study is to identify patients who benefit from ART at an early stage and to select them for this method, and then to continue to offer ART to this patient group. If a relevant reduction in the minimum planning target volume (PTV) margins with ART compared to IGRT is demonstrated in this study, patients could be treated with ART.

NCT ID: NCT06207708 Recruiting - Clinical trials for Head and Neck Cancer

Sarcopenia in Head and Neck Cancer Patients Treated With Curative Hadrontherapy

Start date: April 18, 2023
Phase:
Study type: Observational

The study focuses on the impact of sarcopenia on acute and late toxicities in head and neck tumor affected patients treated with particle therapy.

NCT ID: NCT06203808 Recruiting - Clinical trials for Head and Neck Cancer

Impact in Head and Neck Oncology of Support by a Nurse in the Patient's Care Pathway

COACH-ORL
Start date: February 20, 2024
Phase:
Study type: Observational

Head and neck cancers (HNC) constitute a significant global health burden, ranking fourth in terms of cancer incidence and fifth in terms of cancer-related mortality. The management of HNC requires a complex array of consultations, examinations, rehabilitation, and lifestyle modifications, including addiction cessation. These cancers disproportionately affect economically disadvantaged, socially isolated individuals, and the elderly, resulting in disparities in healthcare access. Health coaching, an approach aimed at improving patients' health and quality of life by supporting behavior and lifestyle changes, has demonstrated effectiveness in various medical fields, including chronic diseases, medical oncology, and hematology. However, its application in head and neck cancer care remains limited, despite its potential benefits for this patient population.

NCT ID: NCT06201039 Not yet recruiting - Clinical trials for Head and Neck Cancer

Continuous Local-anesthetic Wound Infusion for Neck Dissection

CLAWED
Start date: March 1, 2024
Phase: N/A
Study type: Interventional

The goal of this study is to assess the efficacy of continuous local anesthetic wound infusion to improve quality of recovery following ablative surgery and neck dissection.

NCT ID: NCT06192771 Recruiting - Clinical trials for Head and Neck Cancer

Feasibility of Early Swallowing and Speech Intervention for Head and Neck Cancer Patients Treated SURGically

ESSI-SURG
Start date: December 1, 2023
Phase: N/A
Study type: Interventional

Oral cavity cancer (OCC) is one of the most common cancers worldwide, with tongue cancer being one of the most common subtypes. Patients with oral cancers can experience painful swallowing, swallowing difficulty (dysphagia), and associated weight loss long after surgery. Not only is dysphagia an independent predictor of quality of life (QoL) in cancer survivorship, it can also have a devastating impact on the health of patients resulting from complications such as pneumonia, malnutrition and feeding tube dependence. Emerging evidence suggests that patients undergoing surgery benefit from engaging with speech-language pathologists (SLPs) before problems arise, to learn swallow strategies that may become useful in their rehabilitation. This in turn has the potential to reduce complications and minimize the length of feeding tube dependency. This study will assess the feasibility of conducting a prospective clinical trial that would evaluate the effects on patient health, function and overall benefit of early and systematic SLP speech and swallowing intervention for head and neck cancer patients planned for curative surgical treatment. We will also assess long-term changes in select clinical and patient-reported outcomes comparing their status before, and one month after, treatment.

NCT ID: NCT06185738 Not yet recruiting - Breast Cancer Clinical Trials

WeCanManage. An mHealth Self-management Tool

Start date: July 2024
Phase: N/A
Study type: Interventional

Examine the Feasibility, Acceptability, User Satisfaction, and Response Patterns and Preliminary Efficacy on Targeted Patient Reported Outcomes. Using a pre-post, single arm feasibility design with cancer survivors with disabilities